Curated News
By: NewsRamp Editorial Staff
September 25, 2025
Lantern Pharma's AI Platform Challenges Broken Drug Development Model
TLDR
- Lantern Pharma's AI platform RADR offers a competitive edge by accelerating oncology drug development timelines and reducing costs compared to traditional manual methods.
- Lantern Pharma's RADR platform uses over 200 billion oncology data points and 200+ machine learning algorithms to systematically identify and advance promising cancer drug candidates.
- Lantern Pharma's AI-driven approach aims to create more effective cancer treatments faster, potentially improving survival rates and quality of life for patients worldwide.
- Lantern Pharma is pioneering AI in biotech with RADR, a platform analyzing massive datasets to discover novel cancer therapies that traditional methods might miss.
Impact - Why it Matters
This news matters because it highlights a fundamental shift in how cancer treatments are developed, potentially accelerating the delivery of life-saving therapies to patients. Traditional drug development can take over a decade and cost billions, with high failure rates that ultimately delay critical treatments. Lantern Pharma's AI-driven approach could dramatically reduce both time and cost while increasing success rates, meaning new oncology drugs could reach patients faster and at lower costs. For cancer patients and their families, this represents hope for more timely access to innovative treatments. For the healthcare system, it promises more efficient use of research funding and potentially lower drug prices. The adoption of AI in biopharma could revolutionize an industry critical to global health, making this development significant not just for investors but for anyone affected by cancer.
Summary
Lantern Pharma (NASDAQ: LTRN), a Dallas-based clinical-stage biopharmaceutical company, was prominently featured in a Dallas Innovates article covering the 2025 BioNTX iC3 Summit, where industry leaders declared the traditional drug development model "broken." CEO Panna Sharma, who served as both moderator and panelist at the summit, delivered a powerful critique of the current system, stating: "The process of actually making drugs is still largely manual. We have the technology to change that, but the industry hasn't adopted it fast enough." The article emphasized how Lantern Pharma's RADR AI platform represents a transformative approach to oncology drug development, positioning the company at the forefront of efforts to create a more sustainable future for biotech innovation.
The RADR AI platform leverages over 200 billion oncology-focused data points and a library of 200+ advanced machine learning algorithms to streamline drug discovery, accelerate clinical timelines, and significantly reduce development costs. This technology directly addresses the summit's call for greater innovation and efficiency in biopharmaceutical development. Lantern Pharma's growing pipeline includes a Phase 2 clinical program, multiple Phase 1 clinical trials, and an antibody-drug conjugate (ADC) program spanning both solid tumors and blood cancers. The company estimates its AI-driven pipeline has a combined annual market potential exceeding $15 billion USD, potentially providing life-changing therapies to hundreds of thousands of cancer patients worldwide. The article was distributed through BioMedWire, which is part of the Dynamic Brand Portfolio within the Investor Brand Network (IBN), ensuring broad dissemination to investors and industry stakeholders.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Lantern Pharma's AI Platform Challenges Broken Drug Development Model
